tradingkey.logo
tradingkey.logo
Search

Harvard Bioscience Inc

HBIO
Add to Watchlist
8.050USD
+0.130+1.64%
Close 09-23 16:00ET
36.31MMarket Cap
LossP/E TTM

About Harvard Bioscience Inc Company

Harvard Bioscience, Inc. is a developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

Harvard Bioscience Inc Profile

Ticker SymbolHBIO
Company nameHarvard Bioscience Inc
IPO dateOct 21, 2013
CEODuke (John D)
Number of employees330
Security typeOrdinary Share
Fiscal year-endOct 21
Address84 October Hill Rd
CityHOLLISTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code01746-1371
Phone15088938999
Websitehttps://www.harvardbioscience.com/
Ticker SymbolHBIO
IPO dateOct 21, 2013
CEODuke (John D)

Company Executives of Harvard Bioscience Inc

Name
Name/Position
Position
Shareholding
Change
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Independent Director
Independent Director
26.56K
+62.34%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Independent Director
Independent Director
26.56K
+62.34%
Mr. Stephen J. DeNelsky
Mr. Stephen J. DeNelsky
Independent Director
Independent Director
26.56K
+62.34%
Mr. Mark Frost
Mr. Mark Frost
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Ms. Katherine Anne Eade, J.D.
Ms. Katherine Anne Eade, J.D.
Lead Independent Director
Lead Independent Director
58.67K
+28.22%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%
Mr. Robert E. (Rob) Gagnon
Mr. Robert E. (Rob) Gagnon
Independent Director
Independent Director
27.56K
+60.08%

FAQs

Who are the top five shareholders of Harvard Bioscience Inc?

The top five shareholders of Harvard Bioscience Inc are: Ms. Katherine Anne Eade, J.D.

How many institutions hold shares of Harvard Bioscience Inc (HBIO)?

As of 2026Q1, 201 institutions hold shares of Harvard Bioscience Inc, with a combined market value of approximately 2.44M, accounting for 54.17% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -447956.00.

What is the biggest source of revenue for Harvard Bioscience Inc?

In 2026Q1, the Instruments, equipment, software and accessories business generated the highest revenue for Harvard Bioscience Inc, amounting to 20.30M and accounting for 89.34% of total revenue.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.